TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy
Sudeep Pushpakom(University of Liverpool), John Whitehead(Lancaster City Council), Mark Gompels, Terry Foster(University of Liverpool), Saye Khoo(University of Liverpool), Gabriel Schembri, Jane Minton(Leeds Teaching Hospitals NHS Trust), Thomas Jaki(MRC Biostatistics Unit), David Loay, Frank A. Post(King's College Hospital NHS Foundation Trust), Fabiola Martin(Institut de Recerca Biomèdica Catalunya Sud), Clifford Leen, Paula Williamson(University of Liverpool), Cath Spowart(University of Liverpool), Graham J. Kemp(John Radcliffe Hospital), Jiten Vora(University of Liverpool), Elbushra Hereika, Margaret Johnson(Duke University), Satyajit Das, Claire Taylor(University of Liverpool), Ruwanthi Kolamunnage‐Dona(University of Liverpool), Jonathan Ainsworth, Mas Chaponda, Duncan Churchill, Mayur Chauhan, Barry Peters, Marta García‐Fiñana(University of Liverpool), David Chadwick(Lancaster University), Munir Pirmohamed(University of Liverpool)
Cited by 27
Related Papers
Drug repurposing: progress, challenges and recommendations
|Nature Reviews Drug Discovery|2018|4.6k
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias
|PLoS ONE|2008|1.5k
Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia
|New England Journal of Medicine|1986|1.5k
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
|Nature Genetics|2009|1.1k